NCT06225284 - Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions

Triple Negative Breast CancerPremenopausal Breast Cancer

Interventions

DRUG

Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg

After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 7 days of randomization and during neoadjuvant chemotherapy treatment. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.

Trial Locations (1)

100225

RECRUITING

National Taiwan University Hospital, Taipei